{"prompt": "['OSTPDL1', 'Page 47 of 60', 'measurement) of the tumor lesions but the shortest diameter of', 'malignant lymph nodes are used in the RECIST V 1.1 criteria.', '9.1.1 Definitions', 'Evaluable for objective response: Patients who exhibit objective disease', 'progression prior to the end of cycle 1 will be considered evaluable for', 'response. For all other patients, only those patients who have measurable', 'disease present at baseline, have received at least one cycle of therapy,', 'and have had their disease re-evaluated will be considered evaluable for', 'response.', 'Evaluable Non-Target Disease Response: Patients who have lesions', 'present at baseline that are evaluable but do not meet the definitions of', 'measurable disease, have received at least one cycle of therapy, and have', 'had their disease re-evaluated will be considered evaluable for non-', 'target disease. The response assessment is based on the presence,', 'absence, or unequivocal progression of the lesions.', '9.1.2 Disease Parameters', 'Measurable disease: Measurable lesions are defined as those that can be', 'accurately measured in at least one dimension (longest diameter to be', 'recorded) as 20 mm by chest x-ray, as 10 mm with CT scan, or 10', 'mm with calipers by clinical exam. All tumor measurements must be', 'recorded in millimeters (or decimal fractions of centimeters).', 'Note: Tumor lesions that are situated in a previously irradiated area', 'might or might not be considered measurable. If the investigator thinks it', 'appropriate to include them, the conditions under which such lesions', 'should be considered must be defined in the database.', 'Malignant lymph nodes: To be considered pathologically enlarged and', 'measurable, a lymph node must be 15 mm in short axis when assessed', 'by CT scan (CT scan slice thickness no greater than 5 mm). At baseline', 'and in follow-up, only the short axis will be measured and followed.', 'Non-measurable disease: All other lesions (or sites of disease), including', 'small lesions (longest diameter <10 mm or pathological lymph nodes', 'with 10 to <15 mm short axis), are considered non-measurable', 'disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial', 'effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease,', 'and abdominal masses (not followed by CT or MRI), are considered as', 'non-measurable.', 'Note: Cystic lesions that meet the criteria for radiographically defined', 'simple cysts should not be considered as malignant lesions (neither', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 48 of 60', 'measurable nor non-measurable) since they are, by definition, simple', \"cysts. 'Cystic lesions' thought to represent cystic metastases can be\", 'considered as measurable lesions, if they meet the definition of', 'measurability described above. However, if non-cystic lesions are present', 'in the same patient, these are preferred for selection as target lesions.', 'Target lesions: All measurable lesions up to a maximum of 2 lesions per', 'organ and 5 lesions in total, representative of all involved organs, should', 'be identified as target lesions and recorded and measured at baseline.', 'Target lesions should be selected on the basis of their size (lesions with', 'the longest diameter), be representative of all involved organs, but in', 'addition should be those that lend themselves to reproducible repeated', 'measurements. It may be the case that, on occasion, the largest lesion', 'does not lend itself to reproducible measurement in which circumstance', 'the next largest lesion that can be measured reproducibly should be', 'selected. A sum of the diameters (longest for non-nodal lesions, short', 'axis for nodal lesions) for all target lesions will be calculated and', 'reported as the baseline sum diameters. If lymph nodes are to be', 'included in the sum, then only the short axis is added into the sum. The', 'baseline sum diameters will be used as reference to further characterize', 'any objective tumor regression in the measurable dimension of the', 'disease.', 'Non-target lesions: All other lesions (or sites of disease) including any', 'measurable lesions over and above the 5 target lesions should be', 'identified as non-target lesions and should also be recorded at baseline.', 'Measurements of these lesions are not required, but the presence,', 'absence, or in rare cases unequivocal progression of each should be', 'noted throughout follow-up.', '9.1.3 Methods for Evaluation of Measurable Disease', 'All measurements should be taken and recorded in metric notation using', 'a ruler or calipers. The same method of assessment and the same', 'technique should be used to characterize each identified and reported', 'lesion at baseline and during follow-up. Imaging-based evaluation is', 'preferred to evaluation by clinical examination unless the lesion(s) being', 'followed cannot be imaged but are assessable by clinical exam.', 'Clinical lesions: Clinical lesions will only be considered measurable when', 'they are superficial (e.g., skin nodules and palpable lymph nodes) and', '10 mm diameter as assessed using calipers (e.g., skin nodules). In the', 'case of skin lesions, documentation by color photography, including a', 'ruler to estimate the size of the lesion, is recommended.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}